MarketPulse
N

$NRIX

4 articles found
4 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Showcases Protein Degradation Pipeline Potential at AACR 2026

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.
PFESNYGILDNRIXdrug developmentoncology pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Follicular Lymphoma Pipeline Heats Up: 45+ Companies Racing to Expand Treatment Options

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.
BMYCELGrMRKAZNNRIXclinical trialsdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Posts $87.2M Loss While Advancing Bexobrutideg Clinical Pipeline

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.
SNYGILDNRIXclinical trialsimmunology
The Motley FoolThe Motley Fool··Jonathan Ponciano

Redmile Group Doubles Down on Nurix With $63M Investment Despite Underperformance

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.
NRIXKRYSstock underperformanceclinical trial